The incidence of IDH1 gene mutations was more occurred in De novo AML compared to s-AML/t-AML, and there was no significant difference in the occurrence rates of DNMT3A, TET2, and IDH2 gene mutations between these two AML subtypes. The gene discussed is IDH1; the disease is acute myeloid leukemia.